A prognostic view on the application of individualized genomics in Parkinson's disease
- PMID: 23504498
- PMCID: PMC3596092
- DOI: 10.1007/s40142-012-0003-1
A prognostic view on the application of individualized genomics in Parkinson's disease
Abstract
Parkinson's disease is a common age-related progressive neurodegenerative disorder. Over the last 15 years advances have been made in our understanding of the etiology of the disease, with the greatest insights perhaps coming from genetic studies. The identification of a number of genes that harbor pathogenic mutations causing Parkinson's disease have on the whole driven the development of disease model systems and nominated a number of therapeutic targets. As we move towards an era of personalized medicine, genetic determinants will become even more crucial for accurate diagnosis, and assessing prognosis and outcomes. The individual genomic profile and risk assessments will in the long-term determine clinical trial participation, treatment plans and therapeutic dosing. Herein we discuss the status of genetics in Parkinson's disease and how these factors may affect the patient care in the future.
Keywords: Parkinson’s disease; diagnosis; genetics; genomics; individualized medicine.
Conflict of interest statement
The author reported no potential conflicts of interest relevant to this article.
Similar articles
-
Association studies of sporadic Parkinson's disease in the genomic era.Curr Genomics. 2014 Feb;15(1):2-10. doi: 10.2174/1389202914666131210212745. Curr Genomics. 2014. PMID: 24653658 Free PMC article.
-
Advancing Personalized Medicine in Common Forms of Parkinson's Disease through Genetics: Current Therapeutics and the Future of Individualized Management.J Pers Med. 2021 Mar 1;11(3):169. doi: 10.3390/jpm11030169. J Pers Med. 2021. PMID: 33804504 Free PMC article. Review.
-
LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study.Lancet Neurol. 2018 Jul;17(7):597-608. doi: 10.1016/S1474-4422(18)30179-0. Epub 2018 Jun 7. Lancet Neurol. 2018. PMID: 29887161
-
Heredity in Parkinson's disease: new findings.Isr Med Assoc J. 2001 Jun;3(6):435-8. Isr Med Assoc J. 2001. PMID: 11433638 Review.
-
Precision Medicine in Parkinson's Disease: From Genetic Risk Signals to Personalized Therapy.Brain Sci. 2022 Sep 28;12(10):1308. doi: 10.3390/brainsci12101308. Brain Sci. 2022. PMID: 36291241 Free PMC article. Review.
Cited by
-
The Transcriptional Changes of trim Genes Associated with Parkinson's Disease on a Model of Human Induced Pluripotent Stem Cells.Mol Neurobiol. 2017 Nov;54(9):7204-7211. doi: 10.1007/s12035-016-0230-7. Epub 2016 Oct 29. Mol Neurobiol. 2017. PMID: 27796756
-
The role of innate and adaptive immunity in Parkinson's disease.J Parkinsons Dis. 2013;3(4):493-514. doi: 10.3233/JPD-130250. J Parkinsons Dis. 2013. PMID: 24275605 Free PMC article. Review.
-
Common Genetic Variant Association with Altered HLA Expression, Synergy with Pyrethroid Exposure, and Risk for Parkinson's Disease: An Observational and Case-Control Study.NPJ Parkinsons Dis. 2015;1:15002-. doi: 10.1038/npjparkd.2015.2. Epub 2015 Apr 22. NPJ Parkinsons Dis. 2015. PMID: 27148593 Free PMC article.
-
Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson's disease.J Neuroinflammation. 2023 Jun 22;20(1):147. doi: 10.1186/s12974-023-02830-w. J Neuroinflammation. 2023. PMID: 37349821 Free PMC article.
-
Application of clinical blood metabogram for diagnosis of early-stage Parkinson's disease: a pilot study.Front Mol Biosci. 2024 Aug 14;11:1407974. doi: 10.3389/fmolb.2024.1407974. eCollection 2024. Front Mol Biosci. 2024. PMID: 39206052 Free PMC article.
References
-
- Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14:223–36. - PubMed
-
- Ross OA, Farrer MJ. Pathophysiology, pleiotrophy and paradigm shifts: genetic lessons from Parkinson’s disease. Biochemical Society transactions. 2005;33:586–90. - PubMed
-
- Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet. 2009;373:2055–66. - PubMed
-
- Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–40. - PubMed
-
- Rascol O, Lozano A, Stern M, Poewe W. Milestones in Parkinson’s disease therapeutics. Movement disorders. 2011;26:1072–82. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials